scholarly journals Interleukin-13 rs1800925/-1112C/T promoter single nucleotide polymorphism variant linked to anti-schistosomiasis in adult males in Murehwa District, Zimbabwe

PLoS ONE ◽  
2021 ◽  
Vol 16 (5) ◽  
pp. e0252220
Author(s):  
Emilia T. Choto ◽  
Takafira Mduluza ◽  
Moses J. Chimbari
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Eosinophil Infiltration ◽  
Enzyme Linked Immunosorbent Assay ◽  
Amplification Refractory Mutation System ◽  
Adult Males ◽  
Cross Sectional ◽  
Single Nucleotide ◽  
Cytokine Levels

Background Chronic schistosomiasis is predominantly induced through up-regulation of inflammatory cytokines such as interleukin (IL)-13. IL-13 may contribute to the disease outcomes by increasing eosinophil infiltration thereby promoting fibrosis. IL-13 may act as an immunosuppressive inflammatory cytokine that may promote carcinogenesis and also may offer protection against schistosomiasis thereby reducing risk of schistosome infections. Our study evaluated the frequency of the IL-13 rs1800925/-1112 C/ T promoter single nucleotide polymorphisms (SNPs) among schistosomiasis infected individuals and assessed the association of the variants on IL-13 cytokine levels. We also investigated IL-13 rs1800925 polymorphisms on prostate-specific antigen levels as an indicator for risk of prostate cancer development. Methodology The study was cross-sectional and included 50 schistosomiasis infected and 316 uninfected male participants residing in Murehwa District, Zimbabwe. IL-13 rs1800925 SNPs were genotyped by allele amplification refractory mutation system-polymerase chain reaction. Concentrations of serum prostate-specific antigens and plasma IL-13 were measured using enzyme-linked immunosorbent assay. Results Frequencies of the genotypes CC, CT and TT, were 20%, 58% and 22% in schistosomiasis infected, and 18.3%, 62.1% and 19.6% in uninfected participants with no statistical differences. There were significantly (p<0.05) higher IL-13 cytokine levels among both infected and uninfected participants with the genotypes CC and CT; median 92.25 pg/mL and 106.5 pg/mL, respectively, compared to TT variant individuals; 44.78 pg/mL. Within the schistosomiasis uninfected group, CC and CT variants had significantly (p<0.05) higher IL-13 levels; median 135.0 pg/mL and 113.6 pg/mL, respectively compared to TT variant individuals; 47.15 pg/mL. Within the schistosomiasis infected group, CC, CT and TT variant individuals had insignificant differences of IL-13 level. Using logistic regression, no association was observed between prostate-specific antigen levels, IL-13 cytokine levels and IL-13 rs1800925 variants (p>0.05). Conclusion IL-13 rs1800925 C variant individuals had the highest IL-13 cytokine levels among the schistosomiasis uninfected suggesting that they may be protective against Schistosoma infections. There was no association between IL-13 concentrations or IL-13 rs1800925 variants and risk of prostate cancer indicating that IL-13 levels and IL-13 rs10800925 may not be utilised as biomarker for risk of prostate cancer in schistosome infections.

scholarly journals Prostate-Specific Antigen: From Promising to Disappointment Tool for Diagnosis of Chronic Renal Failure in Predialysis Patients

2021 ◽  
Vol 07 (02) ◽  
pp. 082-084
Author(s):  
Ali Abdul Hussein S Al-Janabi
Keyword(s):  
Prostate Cancer ◽  
Renal Failure ◽  
Chronic Renal Failure ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Enzyme Linked Immunosorbent Assay ◽  
Elderly Men ◽  
A Value ◽  
Total Psa ◽  
Moderate Elevation

Abstract Introduction Prostate-specific antigen (PSA) is a biomarker commonly used for detection of prostate cancer. Its viability as a marker for diagnosis of chronic renal failure (CRF) in predialysis patients was investigated. Methods Sera from 230 patients with CRF were analyzed by enzyme-linked immunosorbent assay (ELISA) for determining total PSA (tPSA) levels before hemodialysis. Results Of the patients investigated, 98.69% had a normal PSA level with a value less than 4 ng/mL. Three elderly men with both kidney failure showed a moderate elevation of PSA level. Conclusion PSA is considered a nonsignificant indicator for diagnosis of CRF.

scholarly journals Early detection of prostate cancer local recurrence by urinary prostate-specific antigen

2013 ◽  
Vol 3 (3) ◽  
pp. 213 ◽  
Author(s):  
Stéphane Bolduc ◽  
Brant A. Inman ◽  
Louis Lacombe ◽  
Yves Fradet ◽  
Roland R. Tremblay
Keyword(s):  
Prostate Cancer ◽  
Early Detection ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Laboratory Assessment ◽  
Cross Sectional ◽  
Prostatectomie Radicale ◽  
Psa Recurrence ◽  
Patients Atteints De Cancer

Purpose: We assessed the role of urinary prostate-specific antigen(uPSA) in the follow-up of prostate cancer after retropubic radicalprostatectomy (RRP) for the early detection of local recurrences.Methods: We recruited 50 patients previously treated for prostatecancer with RRP and who had not experienced a prostatespecificantigen (PSA) recurrence within their first postoperativeyear into a cross-sectional laboratory assessment and prospective6-year longitudinal follow-up study. We defined biochemicalfailure as a serum PSA (sPSA) of 0.3 μg/L or greater. Patientsprovided blood samples and a 50-mL sample of first-voided urine.We performed Wilcoxon rank-sum and Fisher exact tests for statisticalanalysis.Results: The median sPSA was 0.13 μg/L. The median uPSA was0.8 μg/L, and was not significantly different when comparingGleason scores or pathological stages. Of the 50 patients, 27 initiallyhad a nondetectable sPSA but a detectable uPSA, and11 patients experienced sPSA failure after 6 years. Six patients haddetectable sPSA and uPSA initially. Fifteen patients were negativefor both sPSA and uPSA, and 13 remained sPSA-free after 6 years.The odds ratio (OR) of having sPSA failure given a positive uPSAtest was 4.5 if sPSA was undetectable, but was reduced to 2.6 ifsPSA was detectable. The pooled Mantel–Haenszel OR of 4.2 suggestedthat a detectable uPSA quadrupled the risk of recurrence,independent of whether sPSA was elevated or not. The sensitivityof uPSA for detecting future sPSA recurrences was 81% andspecificity was 45%.Conclusion: Urinary PSA could contribute to an early detection oflocal recurrences of prostate cancer after a radical prostatectomy.Objectif : Nous avons évalué le rôle de l’antigène prostatiquespécifique (APS) urinaire dans le suivi du cancer de la prostateaprès prostatectomie radicale rétropubienne (PRR) pour le dépistageprécoce de récidives locales.Méthodes : Cinquante patients atteints de cancer de la prostatetraités par PRR et n’ayant présenté aucune récidive avec anomaliede l’APS dans l’année suivant l’intervention chirurgicale ontété inscrits à une étude transversale par épreuves de laboratoireavec suivi longitudinal prospectif sur 6 ans. L’échec sur le planbiochimique était défini comme un taux d’APS sérique de 0,3 μg/Lou plus. Les patients devaient fournir des échantillons de sanget un échantillon d’urine du matin de 50 mL. Les analyses statistiquesreposaient sur le test de Wilcoxon et la méthode exactede Fisher.Résultats : La valeur médiane de l’APS sérique était de 0,13 μg/L.La valeur médiane de l’APS urinaire était de 0,8 μg/L; la différenceétait non significative quand on tenait compte des scores deGleason ou des stades pathologiques. Sur les 50 patients,27 présentaient des taux d’APS sérique non décelables au début,mais des taux d’APS urinaire décelables; 11 patients ont présentéun échec quant aux taux d’APS sérique après 6 ans. Six patientsavaient des taux d’APS sérique et urinaire décelables au départ.Quinze patients n’avaient aucun taux décelable d’APS sérique ouurinaire, et aucun APS sérique n’était toujours décelable chez13 patients après 6 ans. Le rapport de risque d’un échec quantaux taux d’APS sérique après détection d’APS urinaire est de 4,5en l’absence d’un taux d’APS sérique décelable, mais diminueà 2,6 en présence d’un taux d’APS sérique décelable. Le rapportde risque cumulé de 4,21 calculé par la méthode deMantel–Haenszel porte à croire que des taux d’APS urinaire décelablesquadruplent le risque de présenter une récidive, queles taux sériques soient élevés ou non. La sensibilité du test dedépistage de l’APS urinaire pour la détection des récidives avecanomalie des taux sériques était de 81 %, et la spécificité, de 45 %.Conclusion : Le taux d’APS urinaire peut contribuer à un dépistageprécoce des récidives locales après une prostatectomie radicale.

scholarly journals Detecting Novel Urine Biomarkers for the Early Diagnosis of Prostate Cancer: Platelet Derived Growth Factor-BB as a Possible New Target

2018 ◽  
Vol 12 (1) ◽  
pp. 13-19 ◽  
Author(s):  
Athanasios Skarmoutsos ◽  
Ioannis Skarmoutsos ◽  
Ioannis Katafigiotis ◽  
Elisavet Tataki ◽  
Athina Giagini ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Growth Factor ◽  
Early Diagnosis ◽  
Prostate Specific Antigen ◽  
Characteristic Curve ◽  
Specific Antigen ◽  
Predictive Ability ◽  
Platelet Derived Growth Factor ◽  
Enzyme Linked Immunosorbent Assay ◽  
Transrectal Biopsy

Introduction: Although the prostate specific antigen revolutionized the diagnosis of prostate cancer (PCa), it has its limitations. We prospectively examined the potential use of the platelet-derived growth factor-BB (PDGF-BB) as a urine biomarker for the early diagnosis of PCa. Materials and Methods: The urine samples of 118 patients were collected after a prostatic massage and all the patients subsequently underwent ultrasound-guided transrectal biopsy. PDGF-BB was detected in the urine by enzyme-linked immunosorbent assay. Results: Patients with PCa had greater levels of prostate specific antigen and PDGF-BB. Receiver operating characteristic curve analysis showed that the optimal cut-of of PDGF-BB for the prediction of PCa was 1,504.9 with a sensitivity of 60% and a specificity of 51.3%. For a 100 unit increase in PDGF-BB, the likelihood for PCa increased about 4%. Conclusion: PDGF-BB showed a significant predictive ability for PCa. Detection of PDGF-BB in urine with Elisa was easy and improved our diagnostic accuracy in the diagnosis of PCa.

scholarly journals Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms and Prostate Specific Antigen

2019 ◽  
Vol 201 (3) ◽  
pp. 486-495 ◽  
Author(s):  
Sam Li-Sheng Chen ◽  
Jean Ching-Yuan Fann ◽  
Csilla Sipeky ◽  
Teng-Kai Yang ◽  
Sherry Yueh-Hsia Chiu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Single Nucleotide Polymorphisms ◽  
Prostate Specific Antigen ◽  
Risk Prediction ◽  
Specific Antigen ◽  
Nucleotide Polymorphisms ◽  
Single Nucleotide

scholarly journals Catching the Sugars: Electrochemical Aptasensors for the Detection of Cancer-Related Glycosylation Changes in Prostate-Specific Antigen

Proceedings ◽  
2020 ◽  
Vol 60 (1) ◽  
pp. 47
Author(s):  
Ana Díaz-Fernández ◽  
Rebeca Miranda-Castro ◽  
Pedro Estrela ◽  
Noemí de-los-Santos-Álvarez ◽  
María Jesús Lobo-Castañón
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
False Positives ◽  
High Rate ◽  
Enzyme Linked Immunosorbent Assay ◽  
Glycan Structure ◽  
Specific Cancer ◽  
Different Levels ◽  
Selection Of

Prostate-specific Antigen (PSA) is the biomarker that is used for prostate cancer (PCa) detection, although its lack of specificity results in a high rate of false-positives and many unnecessary biopsies. Therefore, there is a need for more specific cancer biomarkers for PCa. Recent studies have shown that the aberrant glycosylation of proteins is a common feature of the presence of cancer. In the case of prostate cancer, there are changes in core-fucose and sialic acids in the glycan structure of PSA. In this work, we describe two different strategies to direct the selection of aptamers toward the glycans of PSA. From these strategies, we identified two aptamers (PSA-1 and PSAG-1) that bind to the glycan structure of PSA with high affinity. Both aptamers were applied in the design of electrochemical aptasensors, in sandwich and direct formats, in order to detect the changes in the glycosylation of PSA. The sensors responded to different levels of PSA in serum, and they showed higher potential to discriminate clinically-meaningful PCa than the ELISA (Enzyme-linked immunosorbent assay) test used in hospitals (reducing the number of false positives), although validation on more samples is needed.

scholarly journals Relationship of Prostate Specific Antigen and Digital Rectal Examination in the Prediction of Prostate Cancer

2020 ◽  
Vol 16 (2) ◽  
pp. 83-87
Author(s):  
Bhusan Raj Timilsina ◽  
Gaurav Devkota ◽  
Shweta Giri ◽  
Sulav Pradhan ◽  
Sudeep RaJ KC
Keyword(s):  
Prostate Cancer ◽  
Diagnostic Accuracy ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Digital Rectal Examination ◽  
Cross Sectional Study ◽  
Medical Sciences ◽  
Cross Sectional ◽  
Rectal Examination ◽  
Relationship Of

Background: Prostate cancer is one of the most common and leading cause of death among different genitourinary causes. However, screening of prostate cancer is limited to Digital Rectal Examination (DRE) and Prostate Specific Antigen (PSA) in Nepal. The aim of this study is to find out which modality is more helpful for the diagnosis of Prostate Cancer. Methods: A retrospective cross-sectional study was conducted in the department of Urology, College of Medical Sciences, Chitwan, Nepal. All patients included in this study were who presented to the OPD with Lower Urinary Tract Symptoms (LUTS). The patients were above the age of 40 with clinical suspicion prostate cancer based on either DRE or PSA.   Results: A total of 150 patients were enrolled from April 2019 to April 2020. Their mean± SD age was of 65.18±9.38 years. The accuracy of the diagnostic test for DRE and PSA were cut off at 4, PSA cut off range of 4 to 10, PSA cut off range of 10 to 30 and PSA cut off at 30 showed that all the screening indices were better for DRE (Sensitivity=100%, Specificity=59.2%, Diagnostic Accuracy=62.2%) than for PSA cut off at 4 (Sensitivity=100%, Specificity=27.6%, Diagnostic Accuracy=32.9%). Among various cut off score or ranges for PSA, cut off score at 30 provided the best screening indices with Sensitivity of 66.7%, Specificity of 97.4% and Diagnostic Accuracy of 95.1%. Conclusions: PSA has higher diagnostic accuracy then DRE. Keywords: DRE; LUTS; Prostate cancer; PSA.  

scholarly journals Blood cadmium levels increase prostate specific antigen and insulin-like growth factor-1 among cadmium exposed workers

2017 ◽  
Vol 36 (1) ◽  
pp. 42 ◽  
Author(s):  
Nendyah Roestijawati ◽  
Lintje Setyawati Maurits ◽  
Sugiyanto Sugiyanto
Keyword(s):  
Prostate Cancer ◽  
Growth Factor ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Absorption Spectrometry ◽  
Cross Sectional ◽  
Exposed Workers ◽  
Spearman Correlation Test ◽  
Relationship Of ◽  
The Relationship

<p>BACKGROUND<br />Cadmium (Cd) is a heavy metal that is classified as a human carcinogen (group IA), one of the cancers that it can cause being prostate cancer. The development of prostate cancer on a molecular basis involves oncogenes such as insuline-like growth factor-1 (IGF-1). Prostate cancer can be detected in the laboratory through the examination of prostate specific antigen (PSA). The present study aimed to determine the relationship of Cd levels with levels of PSA and IGF-1 in exposed and unexposed workers.</p><p>METHODS<br />The study design was cross sectional. The subjects of the studycame from two groups of workers, ie. the group of Cd exposed workers who were welding shop workers and the group of unexposed workers who were office workers. The minimum samplesize was 85 people. The independent variable was blood Cd level. The dependent variables were PSA and IGF-1 levels. Blood Cd levels were measured by atomic absorption spectrometry (AAS), while PSA and IGF-1 were measured using ELISA. Data analysis was performed using the Mann-Whitney test and the Spearman correlation test.</p><p>RESULTS<br />Mean blood Cd level in the exposed workers was 6.5 mg/L and in the unexposed workers 2.15 mg/L. There was a relationship between blood Cd and PSA levels (p&lt;0.05) and between blood Cd levels and IGF-1 (p &lt;0.05).</p><p>CONCLUSIONS<br />There was a relationship of blood Cd with PSA and IGF-1 levels.among workers. PSA and IGF-1 could be a biochemical markers of disease control in cadmium exposed workers.</p>

scholarly journals Prostate Cancer Risk-Associated Single-Nucleotide Polymorphism Affects Prostate-Specific Antigen Glycosylation and Its Function

2019 ◽  
Vol 65 (1) ◽  
pp. e1-e9 ◽  
Author(s):  
Srilakshmi Srinivasan ◽  
Carson Stephens ◽  
Emily Wilson ◽  
Janaththani Panchadsaram ◽  
Kerry DeVoss ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Association Studies ◽  
Specific Antigen ◽  
Prostate Cancer Risk ◽  
Genetic Association Studies ◽  
Glycosylation Site ◽  
Nucleotide Polymorphisms ◽  
Serum Samples ◽  
Single Nucleotide

Abstract BACKGROUND Genetic association studies have reported single-nucleotide polymorphisms (SNPs) at chromosome 19q13.3 to be associated with prostate cancer (PCa) risk. Recently, the rs61752561 SNP (Asp84Asn substitution) in exon 3 of the kallikrein-related peptidase 3 (KLK3) gene encoding prostate-specific antigen (PSA) was reported to be strongly associated with PCa risk (P = 2.3 × 10−8). However, the biological contribution of the rs61752561 SNP to PCa risk has not been elucidated. METHODS Recombinant PSA protein variants were generated to assess the SNP-mediated biochemical changes by stability and substrate activity assays. PC3 cell–PSA overexpression models were established to evaluate the effect of the SNP on PCa pathogenesis. Genotype-specific correlation of the SNP with total PSA (tPSA) concentrations and free/total (F/T) PSA ratio were determined from serum samples. RESULTS Functional analysis showed that the rs61752561 SNP affects PSA stability and structural conformation and creates an extra glycosylation site. This PSA variant had reduced enzymatic activity and the ability to stimulate proliferation and migration of PCa cells. Interestingly, the minor allele is associated with lower tPSA concentrations and high F/T PSA ratio in serum samples, indicating that the amino acid substitution may affect PSA immunoreactivity to the antibodies used in the clinical immunoassays. CONCLUSIONS The rs61752561 SNP appears to have a potential role in PCa pathogenesis by changing the glycosylation, protein stability, and PSA activity and may also affect the clinically measured F/T PSA ratio. Accounting for these effects on tPSA concentration and F/T PSA ratio may help to improve the accuracy of the current PSA test.

Sign in / Sign up

Export Citation Format

Share Document